[Featured Stock] Lapas, World's First Commercialized Microneedle Acne Treatment... Launching into the 7 Trillion Won Global Market

Lapass is showing strong performance. The news that the company passed the current Good Manufacturing Practice (cGMP) inspection for its acne treatment microneedle patch by the U.S. Food and Drug Administration (FDA) appears to be influencing its stock price. Lapass's microneedle technology is the world's only technology protected by a patent until 2033, using its proprietary DEN (Droplet Extension) manufacturing method that includes the drug.

As of 2:59 PM on the 26th, Lapass is trading at 25,950 KRW, up 18.49% from the previous day.

After registering Killa ES (Extra Strength) ODM monograph final track with the FDA in January, Lapass launched the product in the North American market in April through its partner Heyday. The microneedle technology improves drug absorption, addressing the shortcomings of existing topical acne treatments. The product, which protects acne areas in the form of a patch, has received a good response in the North American market, leading to additional orders.

This FDA cGMP certification recognizes not only Lapass's DEN manufacturing technology's mass production capability but also its quality as a pharmaceutical product, marking a world first.

Lapass is preparing to launch its own brand RapMed-2303 (microneedle patch for acne treatment) in the North American market within the fourth quarter of this year. It is also preparing to obtain approval as an over-the-counter drug in the Korean market as an improved new drug.

A Lapass representative said, "cGMP is a standard for excellent pharmaceutical manufacturing and quality management recognized by the FDA. Passing this inspection has laid the foundation for exporting microneedle patch pharmaceuticals to the North American market," adding, "We expect to realize and expand sales in the U.S. and Korea."

According to a report by Persistence Market Research, the global acne treatment market was valued at $5.8 billion (approximately 7 trillion KRW) in 2020. The global acne treatment market is expected to grow at an average annual rate of 6% until 2031.

It was found that about 50 million people in the U.S. receive acne treatment annually. The acne treatment market is dominated by topical administration routes, accounting for 60% based on ease of application and dosage forms such as lotions, creams, and gels. Regionally, North America accounts for about 44%, dominating the global acne treatment market, the report explained.